Skip to Content

Exparel Approval History

  • FDA approved: Yes (First approved October 28th, 2011)
  • Brand name: Exparel
  • Generic name: bupivacaine
  • Dosage form: Injectable Suspension
  • Company: Pacira Pharmaceuticals, Inc.
  • Treatment for: Pain

Exparel (bupivacaine liposome injectable suspension) is a long-acting non-opioid local analgesic for the management of postsurgical pain.

Development History and FDA Approval Process for Exparel

Oct 31, 2011Approval Pacira Pharmaceuticals, Inc. Announces U.S. FDA Approval of Exparel For Postsurgical Pain Management
Jun 14, 2011Pacira Pharmaceuticals, Inc. Announces FDA Extension of Exparel PDUFA Target Date By Three Months
Dec 14, 2010Pacira Pharmaceuticals Announces FDA Acceptance of Exparel New Drug Application for Pain Management

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.